Trial Profile
Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- Sponsors Janssen-Cilag
- 03 Dec 2015 New trial record